This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lefrançois, S.
Right arrow Articles by Jarlier, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lefrançois, S.
Right arrow Articles by Jarlier, V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2007, p. 645-650, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00821-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin{triangledown}

Sébastien Lefrançois, Jérôme Robert, Aurélie Chauffour, Baohong Ji, and Vincent Jarlier*

Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Pierre et Marie Curie (Université Paris 6), and Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France

Received 6 July 2006/ Returned for modification 10 August 2006/ Accepted 25 October 2006

The curing activities of various durations of treatment with a combination of rifampin (RIF) and either streptomycin (STR) or amikacin (AMK) in murine Mycobacterium ulcerans infection were compared in two experiments. In the first experiment, treatment was begun 1 week after infection, when the inflammatory footpad lesion had not yet occurred (preventive model), and in the second experiment, treatment was begun 6 weeks after infection, when inflammatory footpad lesions were established (curative model). In the first experiment, 4 weeks of treatment with daily RIF-STR or RIF-AMK was able to postpone the occurrence of footpad lesion by 12 weeks (RIF-STR) or 17 weeks (RIF-AMK), thus demonstrating their promising bactericidal activities, but neither treatment was able to prevent the late occurrence of footpad lesions. In the second experiment, the overall cure rates, as assessed by the lack of rebound of inflammatory lesions or remultiplication of M. ulcerans, were only 62% after 2 weeks of treatment with RIF and an aminoglycoside and 85% after 4 weeks; but the cure rate reached 100% after 8 or 12 weeks of treatment. The cure rates were slightly higher with the AMK-containing combination than with the STR-containing combination, but the difference was at the limit of significance (P = 0.07). These results show that in the murine model of Buruli ulcer, 8 weeks is the optimal duration of treatment with a combination of RIF and an aminoglycoside.

* Corresponding author. Mailing address: Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Pierre et Marie Curie, site Pitié-Salpêtrière, 91 bd de l'hôpital, 75634 Paris Cedex 13, France. Phone: (33) 1 40 77 97 46. Fax: (33) 1 45 82 75 77. E-mail: vincent.jarlier{at}psl.aphp.fr.

{triangledown} Published ahead of print on 13 November 2006.

Antimicrobial Agents and Chemotherapy, February 2007, p. 645-650, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00821-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ji, B., Chauffour, A., Aubry, A., Robert, J., Ibrahim, M., Jarlier, V. (2009). Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice. Antimicrob. Agents Chemother. 53: 2955-2959 [Abstract] [Full Text]  
  • Ji, B., Chauffour, A., Robert, J., Jarlier, V. (2008). Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice. Antimicrob. Agents Chemother. 52: 1912-1916 [Abstract] [Full Text]  
  • Ji, B., Chauffour, A., Robert, J., Lefrancois, S., Jarlier, V. (2007). Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice. Antimicrob. Agents Chemother. 51: 3737-3739 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»